Pfizer is a biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines across multiple therapeutic areas. The company's portfolio spans cardiovascular disease, infectious disease prevention, oncology, immunology, primary care, and specialty care. Key products include Eliquis (anticoagulant), the Prevnar family (pneumococcal vaccines), Comirnaty (COVID-19 vaccine), Paxlovid (antiviral), Vyndaqel (transthyretin amyloidosis), and Ibrance (oncology). The company also manufactures biosimilars and provides contract manufacturing services.
Pfizer operates through therapeutic area divisions that generated revenue from both primary care products and specialty medicines. Major revenue contributors include vaccines, primary care drugs, specialty care therapies, and oncology treatments. The company maintains strategic partnerships with BioNTech SE on mRNA vaccine development and has collaboration agreements with Bristol-Myers Squibb, Astellas Pharma, Merck KGaA, and others.
Headquartered in New York, Pfizer operates globally with distribution through wholesalers, retail pharmacies, hospitals, government agencies, and integrated healthcare systems. The company was founded in 1849 and is incorporated in Delaware.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $1.36 | $1.37 | -3.5% | |
| 2024 | $1.41 | $1.42 | +281.1% | |
| 2023 | $0.37 | $0.38 | -93.2% | |
| 2022 | $5.47 | $5.59 | +42.1% | |
| 2021 | $3.85 | $3.92 | +125.1% | |
| 2020 | $1.71 | $1.73 | -40.4% | |
| 2019 | $2.87 | $2.92 | +53.5% | |
| 2018 | $1.87 | $1.90 | -46.9% | |
| 2017 | $3.52 | $3.57 | +200.9% | |
| 2016 | $1.17 | $1.18 | +5.4% | |
| 2015 | $1.11 | $1.13 | -21.8% | |
| 2014 | $1.42 | $1.44 | -55.5% | |
| 2013 | $3.19 | $3.23 | +64.4% | |
| 2012 | $1.94 | $1.96 | +52.8% | |
| 2011 | $1.27 | $1.28 | +24.5% | |
| 2010 | $1.02 | $1.03 | -17.1% | |
| 2009 | $1.23 | $1.23 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-26 | 0000078003-26-000026 | SEC ↗ |
| 2024-12-31 | 2025-02-27 | 0000078003-25-000054 | SEC ↗ |
| 2023-12-31 | 2024-02-22 | 0000078003-24-000039 | SEC ↗ |
| 2022-12-31 | 2023-02-23 | 0000078003-23-000024 | SEC ↗ |
| 2021-12-31 | 2022-02-24 | 0000078003-22-000027 | SEC ↗ |
| 2020-12-31 | 2021-02-25 | 0000078003-21-000038 | SEC ↗ |